Olivola M

Ketamine and esketamine during breastfeeding: a systematic review of human pharmacokinetic, infant and lactation outcomes.

Olivola M, Martiadis V, Prodi T +6

ArticlePsilocybin

Psilocybin and ayahuasca in treatment-resistant depression: clinical evidence, methodological constraints and ethical challenges: a narrative review.

Civardi SC, Besana F, Durbano F +4

Glutamatergic Resonance and Dopaminergic Stability: Intranasal Esketamine in Treatment-Resistant Depression with Comorbid ADHD and Autism Spectrum Disorder – A Case Report

Angeletti M, La Monica K, Casati V +9

Dissociation Does Not Mediate Antidepressant Response to Esketamine: A Real-World Longitudinal Study with 6-Month Follow-Up

Olivola M, Martiadis V, La Monica K +8

Like Stepping Outside the Noise: Narrative Experiences of Esketamine-Induced Dissociation in Patients with Treatment-Resistant Depression

Versaci G, Olivola M, La Monica K +11

Personality Disorders and Clinical Response to Intranasal Esketamine in Treatment-Resistant Depression: Trajectories, Modulations, and Psychopathological Reflections

Casati V, La Monica K, Angeletti M +11

Reduction of Suicidality and Depressive Symptoms with Esketamine: Focus on Gender Differences

Martiadis V, Raffone F, Testa S +7

Esketamine-based treatment, depression-specific metacognitive training, and their combination in treatment-resistant depression: 6-month trajectories of depressive symptoms and rumination in a multicenter observational study.

Martiadis V, Raffone F, Atripaldi D +8

Suicidal ideation covaries with depressive severity during six-month real-world esketamine treatment in a cohort enriched for borderline personality disorder.

Martiadis V, Raffone F, Mazzoni F +6

Intranasal esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A multicenter real-world longitudinal study.

Mazzoni F, Raffone F, De Ciechi A +6

Functional outcomes with esketamine in treatment-resistant depression: A 6-month multicenter real-world study.

Guglielmo R, Olivola M, Inuggi A +9

Esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A real-world longitudinal study of suicidal ideation and self-harm.

Raffone F, Mazzoni F, De Ciechi A +6

Cognitive Effects of Esketamine in Treatment-Resistant Depression: A Systematic Review.

Guglielmo R, Facchinetti EL, Cioci D +6

Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression with Comorbid Autism Spectrum Disorder: Three Case Reports.

Guffanti A, Leonardi M, Brondino N +3

Narrative Experiences of Esketamine-Induced Dissociation in Patients with Treatment-Resistant Depression: A Qualitative Exploratory Study.

Olivola M, Prodi T, Versaci G +9

Personalizing esketamine treatment in TRD and TRBD: the role of mentalization, cognitive rigidity, psychache, and suicidality.

Olivola M, Mazzoni F, Tarantino B +12

PreprintKetamine

Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression with Comorbid Autism Spectrum Disorder: Three Case Reports

Guffanti A, Leonardi M, Brondino N +3

Effectiveness of Intranasal Esketamine on Suicidal Ideation and Depressive Symptoms in Patients with Treatment-Resistant Depression: A Longitudinal Study.

Leonardi M, Frediani A, Angeletti MC +10

PreprintKetamine

Effectiveness of Intranasal Esketamine on Suicidal Ideation and Depressive Symptoms in Patients with Treatment-Resistant Depression: A Longitudinal Study, Predictor Analysis and Clinical Implications

Leonardi M, Frediani A, Angeletti MC +10

Mentalization and Emotional-Cognitive Rigidity as predictors of esketamine's effects on Treatment-Resistant Depression: Findings from a prospective observational study.

Olivola M, Mazzoni F, Tarantino B +11

Depression and suicidal risk in autism spectrum disorder: efficacy of intranasal esketamine. Clinical experience from a public mental health service in Italy

Guffanti A, Mazzoni F, Silva A +4

“Improvements in Reflective Functioning in Patients with Treatment-Resistant Depression and Personality Disorder Treated with Esketamine”

Olivola M, Mazzoni F, Alessandro G +3

Esketamine Treatment Trajectory of Patients with Treatment-Resistant Depression in the Mid and Long-Term Run: Data from REAL-ESK Study Group.

Rosso G, d'Andrea G, Barlati S +15